Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/20/2024 | $24.00 | Buy | Chardan Capital Markets |
| 10/14/2024 | $18.00 | Outperform | Leerink Partners |
| 3/26/2024 | Market Perform → Outperform | TD Cowen | |
| 11/20/2023 | Neutral | JP Morgan | |
| 7/25/2023 | Outperform → Market Perform | TD Cowen | |
| 5/1/2023 | $9.00 → $12.00 | Underperform → Neutral | BofA Securities |
| 4/26/2023 | $24.00 | Buy | Canaccord Genuity |
| 1/6/2023 | $22.00 → $9.00 | Buy → Underperform | BofA Securities |
SCHEDULE 13G - Stoke Therapeutics, Inc. (0001623526) (Subject)
8-K - Stoke Therapeutics, Inc. (0001623526) (Filer)
8-K - Stoke Therapeutics, Inc. (0001623526) (Filer)